Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases
CD38 is an antigen known to be expressed on tumor cells of multiple myeloma, lymphoma, and AML patients.
“We believe that using a CD38-specific antibody to direct ACTR attack has the potential to provide meaningful therapeutic benefit to CD38 expressing malignancies, including AML patients for whom treatment options continue to be very limited,” said
CD38 is a difficult antigen to target using conventional T cell therapies, like CAR-T, because it is expressed on T cells. Expression on T cells drives “fratricide” during manufacturing, a process where activated T cells begin to attack and kill themselves. Since ACTR T cells require a targeting antibody to be activated and the targeting antibody is not present during manufacturing, ACTR T cells can be manufactured without triggering self-attack. As a result, ACTR has the potential to pursue T cell targets like CD38.
Presentation Title: Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab Over CAR-based Approaches
Presentation Time: 4:05 PM
About Unum Therapeutics
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Unum’s novel proprietary technology, Antibody-Coupled T cell Receptor (ACTR), is a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. ACTR087 used in combination with rituximab, an anti-CD20 antibody, is Unum’s most advanced product candidate, currently in Phase I clinical testing in adult patients with relapsed or refractory non-Hodgkin lymphoma (r/r
The Company is headquartered in Cambridge, MA.
Forward looking Statements
This press release contains forward-looking statements. Statements in this press release about our future expectations, plans and prospects, including projections regarding future revenues and financing performance, our long-term growth, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates, including the four lead ACTR product candidates, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the
Stern Investor Relations, Inc.
Source: Unum Therapeutics Inc.